Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer

Gynecologic Oncology

Volumn 130, Issue 3, 2013, Pages 426-430

  Lowery, William J ^a   Lowery, Ashlei W ^a   Barnett, Jason C ^b   Lopez Acevedo, Micael ^a   Lee, Paula S ^a   Secord, Angeles Alvarez ^a   Havrilesky, Laura ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b San Antonio Uniformed Services Health Education Consortium   (United States)

Author keywords

Cost effectiveness; Palliative care; Platinum resistant ovarian cancer

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EMERGENCY WARD; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LUNG CANCER; MEDICAL SPECIALIST; OVARY CANCER; PALLIATIVE THERAPY; PATIENT REFERRAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SENSITIVITY ANALYSIS;

COST EFFECTIVENESS; PALLIATIVE CARE; PLATINUM RESISTANT OVARIAN CANCER;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG RESISTANCE, NEOPLASM; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; NEOPLASM METASTASIS; ODDS RATIO; OVARIAN NEOPLASMS; PALLIATIVE CARE; PLATINUM COMPOUNDS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TERMINAL CARE;

EID: 84882455195     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.06.011     Document Type: Article

References (38)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J. Clin. 62 1 Jan-Feb 2012 10 29
2. R.W. Naumann, and R.L. Coleman Management strategies for recurrent platinum-resistant ovarian cancer Drugs 71 11 Jul 30 2011 1397 1412
3. G. Blackledge, F. Lawton, C. Redman, and K. Kelly Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials Br. J. Cancer 59 4 Apr 1989 650 653
4. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. Oncol. 19 14 Jul 15 2001 3312 3322
5. M. Bruzzone, M.G. Centurioni, P. Giglione, M. Gualco, D.F. Merlo, and L. Miglietta Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study Oncology 80 3-4 2011 238 246
6. G. Crespo, M. Sierra, R. Losa, J.P. Berros, N. Villanueva, and J. Fra Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study Int. J. Gynecol. Cancer 21 3 Apr 2011 478 485
7. K.F. McGonigle, H.G. Muntz, J. Vuky, P.J. Paley, D.S. Veljovich, and B.E. Greer Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study Cancer 117 16 Aug 15 2011 3731 3740
8. E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, and G. Kristensen AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J. Clin. Oncol. 30 2012 [Supplemental; abstract]
9. Center to Advance Palliative Care Available from: www.capc.org
10. M.H. Levy, A. Back, C. Benedetti, J.A. Billings, S. Block, and B. Boston NCCN clinical practice guidelines in oncology: palliative care J. Natl. Compr. Canc. Netw. 7 4 Apr 2009 436 473
11. P. Kumar, D. Casarett, A. Corcoran, K. Desai, Q. Li, and J. Chen Utilization of supportive and palliative care services among oncology outpatients at one academic cancer center: determinants of use and barriers to access J. Palliat. Med. 15 8 Aug 2012 923 930
12. J. Fauci, K. Schneider, C. Walters, J. Boone, J. Whitworth, and E. Killian The utilization of palliative care in gynecologic oncology patients near the end of life Gynecol. Oncol. 127 1 Oct 2012 175 179
13. J.S. Temel, J.A. Greer, A. Muzikansky, E.R. Gallagher, S. Admane, and V.A. Jackson Early palliative care for patients with metastatic non-small-cell lung cancer N. Engl. J. Med. 363 8 Aug 19 2010 733 742
14. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J. Clin. Oncol. 25 33 Nov 20 2007 5180 5186
15. S. Lutz, R. Norrell, C. Bertucio, L. Kachnic, C. Johnson, and D. Arthur Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital J. Palliat. Med. 4 2 Summer 2001 157 165
16. T. Morita, T. Akechi, M. Ikenaga, Y. Kizawa, H. Kohara, and T. Mukaiyama Late referrals to specialized palliative care service in Japan J. Clin. Oncol. 23 12 Apr 20 2005 2637 2644
17. C. Zimmermann, R. Riechelmann, M. Krzyzanowska, G. Rodin, and I. Tannock Effectiveness of specialized palliative care: a systematic review JAMA 299 14 Apr 9 2008 1698 1709
18. L. Barbera, L. Elit, M. Krzyzanowska, R. Saskin, and A.S. Bierman End of life care for women with gynecologic cancers Gynecol. Oncol. 118 2 Aug 1 2010 196 201
19. S.N. Lewin, B.M. Buttin, M.A. Powell, R.K. Gibb, J.S. Rader, and D.G. Mutch Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol. Oncol. 99 2 Nov 2005 261 266
20. L.J. Havrilesky, G. Broadwater, D.M. Davis, K.C. Nolte, J.C. Barnett, and E.R. Myers Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment Gynecol. Oncol. 113 2 May 2009 216 220
21. F.J. Meyers, and J. Linder Simultaneous care: disease treatment and palliative care throughout illness J. Clin. Oncol. 21 7 Apr 1 2003 1412 1415
22. D.E. Weissman Decision making at a time of crisis near the end of life JAMA 292 14 Oct 13 2004 1738 1743
23. A. El-Jawahri, J.A. Greer, and J.S. Temel Does palliative care improve outcomes for patients with incurable illness? A review of the evidence J. Support. Oncol. 9 3 May-Jun 2011 87 94
24. S. Yennurajalingam, D.L. Urbauer, K.L. Casper, C.C. Reyes-Gibby, R. Chacko, and V. Poulter Impact of a palliative care consultation team on cancer-related symptoms in advanced cancer patients referred to an outpatient supportive care clinic J. Pain Symptom Manage. 41 1 Jan 2011 49 56
25. M. Follwell, D. Burman, L.W. Le, K. Wakimoto, D. Seccareccia, and J. Bryson Phase II study of an outpatient palliative care intervention in patients with metastatic cancer J. Clin. Oncol. 27 2 Jan 10 2009 206 213
26. M.O. Delgado-Guay, H.A. Parsons, Z. Li, L.J. Palmer, and E. Bruera Symptom distress, interventions, and outcomes of intensive care unit cancer patients referred to a palliative care consult team Cancer 115 2 Jan 15 2009 437 445
27. D. Casarett, M. Johnson, D. Smith, and D. Richardson The optimal delivery of palliative care: a national comparison of the outcomes of consultation teams vs. inpatient units Arch. Intern. Med. 171 7 Apr 11 2011 649 655
28. I.J. Higginson, and C.J. Evans What is the evidence that palliative care teams improve outcomes for cancer patients and their families? Cancer J. 16 5 Sep-Oct 2010 423 435
29. E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist, V. Gebski, M. Heywood, and P.A. Vasey Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J. Clin. Oncol. 28 20 Jul 10 2010 3323 3329
30. J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, and A.J. Lacave Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J. Clin. Oncol. 24 29 Oct 10 2006 4699 4707
31. M.K. Parmar, J.A. Ledermann, N. Colombo, A. du Bois, J.F. Delaloye, and G.B. Kristensen Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 9375 Jun 21 2003 2099 2106
32. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, and A. Husain OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J. Clin. Oncol. 30 17 Jun 10 2012 2039 2045
33. E. Pujade-Lauraine AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) 2012 American Society of Clinical Oncology Chicago, IL
34. R.P. Rocconi, A.S. Case, J.M. Straughn Jr., J.M. Estes, and E.E. Partridge Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis Cancer 107 3 Aug 1 2006 536 543
35. C. Doyle, M. Crump, M. Pintilie, and A.M. Oza Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer J. Clin. Oncol. 19 5 Mar 1 2001 1266 1274
36. J.C. Weeks, P.J. Catalano, A. Cronin, M.D. Finkelman, J.W. Mack, and N.L. Keating Patients' expectations about effects of chemotherapy for advanced cancer N. Engl. J. Med. 367 17 Oct 25 2012 1616 1625
37. E.A. Keyser, B.G. Reed, W.J. Lowery, M.J. Sundborg, W.E. Winter III, and J.A. Ward Hospice enrollment for terminally ill patients with gynecologic malignancies: impact on outcomes and interventions Gynecol. Oncol. 118 3 Sep 2010 274 277
38. J.A. Greer, W.F. Pirl, V.A. Jackson, A. Muzikansky, I.T. Lennes, and R.S. Heist Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer J. Clin. Oncol. 30 4 Feb 1 2012 394 400